ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Oct 21, 2024 · CIK: 1715925
Sentiment: neutral
Topics: filing, press-release
TL;DR
IPA files 6-K with press release, no new financial details yet.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 21, 2024, to report a press release dated October 21, 2024. The filing does not contain specific financial figures or operational updates beyond the announcement of the press release itself.
Why It Matters
This filing indicates that ImmunoPrecise Antibodies Ltd. has made a public announcement, the details of which are contained in an attached press release, potentially impacting investor understanding of the company's recent activities.
Risk Assessment
Risk Level: low — The filing is a routine report of a press release and does not contain new material financial information or operational changes that would immediately alter risk.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- Kristin Taylor (person) — Signatory for the company
- October 21, 2024 (date) — Date of press release and filing
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release dated October 21, 2024, issued by ImmunoPrecise Antibodies Ltd.
What is the filing date of this Form 6-K?
This Form 6-K was filed as of October 21, 2024.
Which exhibit is attached to this 6-K filing?
Exhibit 99.1, a Press Release dated October 21, 2024, is attached to this 6-K filing.
Who signed this Form 6-K on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor signed this Form 6-K on behalf of ImmunoPrecise Antibodies Ltd.
Does this filing include annual reports under Form 20-F or 40-F?
The registrant indicates it files annual reports under Form 20-F, as indicated by the checkmark next to 'Form 20-F'.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-10-21 09:08:58
Filing Documents
- press_release_oct_21_202.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 11KB
- 0000950170-24-115773.txt ( ) — 33KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: October 21, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer